Intrinsiqq
Lifecore Biomedical, Inc. logo

Lifecore Biomedical, Inc. Quality Score

LFCR

⊜ Compare
Quality0

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Revenue Growth
0/100
-13.6%

Below 2%, essentially flat

Business Quality & Capital Allocation

Share Dilution
0/100
28.8%

Heavy dilution above 5%

Margin Trend
0/100
-5.0pp

Contracted >2pp, margin pressure

Capital Structure
0/100
$146M

Positive debt with no FCF to service it

2020
$360000
$144M
2021
$1.00M
$192M
2022
$2.00M
$113M
2023
$19.0M
$96.0M
TTM
$17.0M
$163M
CashDebt
Return on Capital
0/100
-11.5%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Lifecore Biomedical (LFCR) quality: score, margins and returns

Lifecore Biomedical (LFCR) scores 0/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 5 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Lifecore Biomedical (LFCR) a high-quality business?+

Lifecore Biomedical scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Lifecore Biomedical's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from LFCR's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Lifecore Biomedical scores well and where it falls behind.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 29 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Fiscal year ends May. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with LFCR

CompareIntrinsic value
ASRTAssertio Holdings Inc.
$9.09+0.28%10
TBPHTheravance Biopharma Inc.
No recent price82
XNCRXencor Inc.
$35.01+14.28%0
ETONEton Pharmaceuticals Inc.
$50.72-0.45%75
SEPNSepterna, Inc.
$47.88+9.57%46
AGIOAgios Pharmaceuticals Inc.
$31.38+0.58%40
GYREGyre Therapeutics Inc.
$4.44+0.00%18
SPRYArs Pharmaceuticals Inc
$3.05+0.00%40

Held by ETFs

LFCR is in 5 US ETFs. The largest of them, with LFCR's weight in each:

Spot a number that looks wrong? Check it in LFCR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LFCR

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.